340 related articles for article (PubMed ID: 33681816)
21. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
Inoue S; Li WY; Tseng A; Beerman I; Elia AJ; Bendall SC; Lemonnier F; Kron KJ; Cescon DW; Hao Z; Lind EF; Takayama N; Planello AC; Shen SY; Shih AH; Larsen DM; Li Q; Snow BE; Wakeham A; Haight J; Gorrini C; Bassi C; Thu KL; Murakami K; Elford AR; Ueda T; Straley K; Yen KE; Melino G; Cimmino L; Aifantis I; Levine RL; De Carvalho DD; Lupien M; Rossi DJ; Nolan GP; Cairns RA; Mak TW
Cancer Cell; 2016 Aug; 30(2):337-348. PubMed ID: 27424808
[TBL] [Abstract][Full Text] [Related]
22. PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.
Aivalioti MM; Bartholdy BA; Pradhan K; Bhagat TD; Zintiridou A; Jeong JJ; Thiruthuvanathan VJ; Pujato M; Paranjpe A; Zhang C; Levine RL; Viny AD; Wickrema A; Verma A; Will B
Blood Cancer Discov; 2022 Sep; 3(5):444-467. PubMed ID: 35820129
[TBL] [Abstract][Full Text] [Related]
23. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.
Yang H; Liu Y; Bai F; Zhang JY; Ma SH; Liu J; Xu ZD; Zhu HG; Ling ZQ; Ye D; Guan KL; Xiong Y
Oncogene; 2013 Jan; 32(5):663-9. PubMed ID: 22391558
[TBL] [Abstract][Full Text] [Related]
24. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
[TBL] [Abstract][Full Text] [Related]
25. STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation.
Xie J; Sheng M; Rong S; Zhou D; Wang C; Wu W; Huang J; Sun Y; Wang Y; Chen P; Wu Y; Wang Y; Wang L; Zhou BO; Huang X; Walsh CP; Bohlander SK; Huang J; Wang X; Xu GL; Gao H; Shi Y
Leukemia; 2023 Dec; 37(12):2457-2467. PubMed ID: 37816954
[TBL] [Abstract][Full Text] [Related]
26. An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis.
Cheng J; Guo S; Chen S; Mastriano SJ; Liu C; D'Alessio AC; Hysolli E; Guo Y; Yao H; Megyola CM; Li D; Liu J; Pan W; Roden CA; Zhou XL; Heydari K; Chen J; Park IH; Ding Y; Zhang Y; Lu J
Cell Rep; 2013 Oct; 5(2):471-81. PubMed ID: 24120864
[TBL] [Abstract][Full Text] [Related]
27. Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells.
Gerecke C; Schumacher F; Berndzen A; Homann T; Kleuser B
Epigenetics; 2020 Mar; 15(3):307-322. PubMed ID: 31505989
[TBL] [Abstract][Full Text] [Related]
28. TET2 deficiency leads to stem cell factor-dependent clonal expansion of dysfunctional erythroid progenitors.
Qu X; Zhang S; Wang S; Wang Y; Li W; Huang Y; Zhao H; Wu X; An C; Guo X; Hale J; Li J; Hillyer CD; Mohandas N; Liu J; Yazdanbakhsh K; Vinchi F; Chen L; Kang Q; An X
Blood; 2018 Nov; 132(22):2406-2417. PubMed ID: 30254129
[TBL] [Abstract][Full Text] [Related]
29. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.
Jeong JJ; Gu X; Nie J; Sundaravel S; Liu H; Kuo WL; Bhagat TD; Pradhan K; Cao J; Nischal S; McGraw KL; Bhattacharyya S; Bishop MR; Artz A; Thirman MJ; Moliterno A; Ji P; Levine RL; Godley LA; Steidl U; Bieker JJ; List AF; Saunthararajah Y; He C; Verma A; Wickrema A
Cancer Discov; 2019 Jun; 9(6):778-795. PubMed ID: 30944118
[TBL] [Abstract][Full Text] [Related]
30. Consequences of mutant TET2 on clonality and subclonal hierarchy.
Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
[TBL] [Abstract][Full Text] [Related]
31. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K
Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061
[TBL] [Abstract][Full Text] [Related]
32. Roles of IDH1/2 and TET2 mutations in myeloid disorders.
Inoue S; Lemonnier F; Mak TW
Int J Hematol; 2016 Jun; 103(6):627-33. PubMed ID: 26980223
[TBL] [Abstract][Full Text] [Related]
33. Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
Jing CB; Prutsch N; He S; Zimmerman MW; Landesman Y; Look AT
Br J Haematol; 2023 May; 201(3):489-501. PubMed ID: 36746437
[TBL] [Abstract][Full Text] [Related]
34. [TET2 as a gatekeeper for hematologic malignancies].
Muto H; Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
[TBL] [Abstract][Full Text] [Related]
35. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.
Guan Y; Greenberg EF; Hasipek M; Chen S; Liu X; Kerr CM; Gackowski D; Zarakowska E; Radivoyevitch T; Gu X; Willard B; Visconte V; Makishima H; Nazha A; Mukherji M; Sekeres MA; Saunthararajah Y; Oliński R; Xu M; Maciejewski JP; Jha BK
Commun Biol; 2020 Sep; 3(1):493. PubMed ID: 32895473
[TBL] [Abstract][Full Text] [Related]
36. DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages.
Cobo I; Tanaka TN; Chandra Mangalhara K; Lana A; Yeang C; Han C; Schlachetzki J; Challcombe J; Fixsen BR; Sakai M; Li RZ; Fields H; Mokry M; Tsai RG; Bejar R; Prange K; de Winther M; Shadel GS; Glass CK
Immunity; 2022 Aug; 55(8):1386-1401.e10. PubMed ID: 35931086
[TBL] [Abstract][Full Text] [Related]
37. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.
Fuster JJ; MacLauchlan S; Zuriaga MA; Polackal MN; Ostriker AC; Chakraborty R; Wu CL; Sano S; Muralidharan S; Rius C; Vuong J; Jacob S; Muralidhar V; Robertson AA; Cooper MA; Andrés V; Hirschi KK; Martin KA; Walsh K
Science; 2017 Feb; 355(6327):842-847. PubMed ID: 28104796
[TBL] [Abstract][Full Text] [Related]
38.
Kunimoto H; McKenney AS; Meydan C; Shank K; Nazir A; Rapaport F; Durham B; Garrett-Bakelman FE; Pronier E; Shih AH; Melnick A; Chaudhuri J; Levine RL
Blood; 2017 Mar; 129(13):1779-1790. PubMed ID: 28077417
[TBL] [Abstract][Full Text] [Related]
39. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.
Busque L; Patel JP; Figueroa ME; Vasanthakumar A; Provost S; Hamilou Z; Mollica L; Li J; Viale A; Heguy A; Hassimi M; Socci N; Bhatt PK; Gonen M; Mason CE; Melnick A; Godley LA; Brennan CW; Abdel-Wahab O; Levine RL
Nat Genet; 2012 Nov; 44(11):1179-81. PubMed ID: 23001125
[TBL] [Abstract][Full Text] [Related]
40. The TET2 interactors and their links to hematological malignancies.
Pan F; Weeks O; Yang FC; Xu M
IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
